Medtronic (MDT) EBITDA Margin (2014 - 2026)

Medtronic has disclosed EBITDA Margin across 13 years of filings, most recently posting 18.08% for Q3 2026.

• In Q3 2026, EBITDA Margin rose 124.0% year-over-year to 18.08%; the TTM figure through Jul 2026 stood at 18.08% (up 18.0% YoY), while the FY2026 annual figure was 17.78%, up 3.0% from the prior year.
• EBITDA Margin came in at 18.08% for Q3 2026 at Medtronic, down from 19.1% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 21.37% in Q1 2022 to a low of 12.26% in Q2 2024.
• Average EBITDA Margin over 5 years is 17.69%, with a median of 18.08% recorded in 2026.
• Year-over-year, EBITDA Margin surged 495 bps in 2022 and slumped 605 bps in 2024.
• Over 5 years, EBITDA Margin stood at 18.51% in 2022, then dropped by 9 bps to 16.78% in 2023, then increased by 13 bps to 18.98% in 2024, then fell by 1 bps to 18.81% in 2025, then fell by 4 bps to 18.08% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 18.08% in Q3 2026, 19.1% in Q2 2026, and 16.24% in Q1 2026.